Company Analysis

Evogene Ltd (EVGN)

Nasdaq: EVGN · Agricultural Chemicals · Rehovot, IL · filing with the SEC since 2013
Grade4.0
◀ Past 3.5● Present 4.2▶ Future 4.4
2 est.
The companyfiscal 2025, as filed
Revenue$3.9M-30.9%
Net income-$7.8M+56.6%
Earnings per share$1.08+137.2%
Operating cash flow-$13.5M+31.5%
Cash$13.0M-15.3%
Debtn/a
Shareholders’ equity$12.0M-19.3%
Shares, diluted7,874,039+38.2%
Return on equity-65.4%
The recordfrom its filings
Filings in 202667
Newest filingNov 10 · 6-K
Annual reportMar 26, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$700,000
Patents granted117
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Sep 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton EVGN · research, not advice